Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Jason R Westin, Frederick L Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B Miklos, Matthew L Ulrickson, Miguel-Angel Perales, Umar Farooq, Luciano Wannesson, Lori Leslie, Marie José Kersten, Caron A Jacobson, John M Pagel, Gerald Wulf, Patrick Johnston, Aaron P Rapoport, Linqiu Du, Saran Vardhanabhuti, Simone Filosto, Jina Shah, Julia T Snider, Paul Cheng, Christina To, Olalekan O Oluwole, Anna Sureda, Jason R Westin, Frederick L Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B Miklos, Matthew L Ulrickson, Miguel-Angel Perales, Umar Farooq, Luciano Wannesson, Lori Leslie, Marie José Kersten, Caron A Jacobson, John M Pagel, Gerald Wulf, Patrick Johnston, Aaron P Rapoport, Linqiu Du, Saran Vardhanabhuti, Simone Filosto, Jina Shah, Julia T Snider, Paul Cheng, Christina To, Olalekan O Oluwole, Anna Sureda
Abstract
Purpose: Older patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) may be considered ineligible for curative-intent therapy including high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). Here, we report outcomes of a preplanned subgroup analysis of patients ≥65 years in ZUMA-7.
Patients and methods: Patients with LBCL refractory to or relapsed ≤12 months after first-line chemoimmunotherapy were randomized 1:1 to axicabtagene ciloleucel [axi-cel; autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy] or standard of care (SOC; 2-3 cycles of chemoimmunotherapy followed by HDT-ASCT). The primary endpoint was event-free survival (EFS). Secondary endpoints included safety and patient-reported outcomes (PROs).
Results: Fifty-one and 58 patients aged ≥65 years were randomized to axi-cel and SOC, respectively. Median EFS was greater with axi-cel versus SOC (21.5 vs. 2.5 months; median follow-up: 24.3 months; HR, 0.276; descriptive P < 0.0001). Objective response rate was higher with axi-cel versus SOC (88% vs. 52%; OR, 8.81; descriptive P < 0.0001; complete response rate: 75% vs. 33%). Grade ≥3 adverse events occurred in 94% of axi-cel and 82% of SOC patients. No grade 5 cytokine release syndrome or neurologic events occurred. In the quality-of-life analysis, the mean change in PRO scores from baseline at days 100 and 150 favored axi-cel for EORTC QLQ-C30 Global Health, Physical Functioning, and EQ-5D-5L visual analog scale (descriptive P < 0.05). CAR T-cell expansion and baseline serum inflammatory profile were comparable in patients ≥65 and <65 years.
Conclusions: Axi-cel is an effective second-line curative-intent therapy with a manageable safety profile and improved PROs for patients ≥65 years with R/R LBCL.
©2023 The Authors; Published by the American Association for Cancer Research.
Figures
References
- Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients. Oncologist 2021;26:120–32.
- Surveillance Epidemiology and End Results. Cancer Stat Facts: NHL — Diffuse Large B-Cell Lymphoma (DLBCL); 2022. Available from: .
- Neelapu SS, Jacobson CA, Oluwole OO, Munoz J, Deol A, Miklos DB, et al. . Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 2020;135:2106–9.
- Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011;2011:498–505.
- Lahoud OB, Sauter CS, Hamlin PA, Dahi PB. High-dose chemotherapy and autologous stem cell transplant in older patients with lymphoma. Curr Oncol Rep 2015;17:42.
- YESCARTA®. (axicabtagene ciloleucel). Summary of product characteristics. Amsterdam, the Netherlands: Kite Pharma EU B.V.; 2022.
- YESCARTA, Kite Pharma Inc. YESCARTA® (axicabtagene ciloleucel) suspension for intravenous infusion. U.S. Prescribing Information. Santa Monica, CA: Kite Pharma Inc; 2021.
- Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. . Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386:640–54.
- Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. . Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531–44.
- Lin V, Oak B, Snider J, Epstein J. Health-related quality of life (HRQOL) burden in patients with relapsed/refractory diffuse large B-cell lymphoma (RR-DLBCL) and non-Hodgkin's lymphoma (RR-NHL). J Clin Oncol 2020;38(15_suppl):e20070–e.
- Hafez R, Hussein S, Ismail M. Definitive salvage chemotherapy for the treatment of refractory/relapsed non-Hodgkin lymphoma, a single center experience. Alexandria J Med 2019;54:679–83.
- Oerlemans S, Issa DE, van den Broek EC, Nijziel MR, Coebergh JW, Huijgens PC, et al. . Health-related quality of life and persistent symptoms in relation to (R-)CHOP14, (R-)CHOP21, and other therapies among patients with diffuse large B-cell lymphoma: results of the population-based PHAROS-registry. Ann Hematol 2014;93:1705–15.
- U.S. Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims; 2009.
- U.S. Food and Drug Administration. Guidance for industry: core patient-reported outcomes in cancer clinical trials guidance for industry; 2021.
- European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: The use of patient-reported outcome (PRO) measures in oncology studies; 2016. Available from: .
- Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375–90.
- Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059–68.
- Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. . Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–95.
- Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, et al. . Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015;16:57–66.
- Locke FL, Rossi JM, Neelapu SS, Jacobson CA, Miklos DB, Ghobadi A, et al. . Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 2020;4:4898–911.
- Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, et al. . Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med 2020;26:270–80.
- Locke FL, Chou J, Vardhanabhuti S, Perbost R, Dreger P, Hill BT, et al. . Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). J Clin Oncol 2022;40(16_suppl):7565.
- Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Communications in Statistics - Theory and Methods 1991;20:2609–31.
- Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, et al. . Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 2022;140:2248–60.
- Elsawy M, Chavez JC, Avivi I, Larouche J-F, Cwynarski LWK, Osman K, et al. . Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (axi-cel) versus standard of care therapy in patients with relapsed/refractory large B-cell lymphoma (ZUMA-7). Blood 2021;138:430.
- Maringwa JT, Quinten C, King M, Ringash J, Osoba D, Coens C, et al. . Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. Support Care Cancer 2011;19:1753–60.
- Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70.
- Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021;384:842–58.
- Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, et al. . Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Ann Oncol 2015;26:1058–68.
- Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D, et al. . Autologous stem cell transplantation in elderly patients (>or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European blood and marrow transplantation registry. Haematologica 2008;93:1837–42.
- Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, et al. . Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. Am J Hematol 2017;92:E529–E33.
- Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood 2022;139:2737–46.
- Tchalla AE, Wellenius GA, Travison TG, Gagnon M, Iloputaife I, Dantoine T, et al. . Circulating vascular cell adhesion molecule-1 is associated with cerebral blood flow dysregulation, mobility impairment, and falls in older adults. Hypertension 2015;66:340–6.
- Richter V, Rassoul F, Purschwitz K, Hentschel B, Reuter W, Kuntze T. Circulating vascular cell adhesion molecules VCAM-1, ICAM-1, and E-selectin in dependence on aging. Gerontology 2003;49:293–300.
- Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. . Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 2019;20:31–42.
- Castaneda-Puglianini O, Chavez JC. Assessing and management of neurotoxicity after CAR-T therapy in diffuse large B-cell lymphoma. J Blood Med 2021;12:775–83.
- Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, et al. . Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 2020;4:3123–7.
- Filosto S, Vardhanabhuti S, Canales M, Poiré X, Lekakis LJ, de Vos S, et al. . Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma. Cancer Res 2022;82:CT004–CT.
- Tariq A, Katiyar V, Aijaz T. Safety of anti-CD-19 chimeric antigen receptor T-cell therapy in the older population with diffuse large B cell lymphoma: a meta-analysis. Blood 2021;138:4814.
- BREYANZI® JT, Inc., a Bristol-Myers Squibb Company. BREYANZI® (lisocabtagene maraleucel) suspension for intravenous infusion. U.S. Prescribing Information. Seattle, WA. Revised June 2022.
- Oluwole OO, Bouabdallah K, Munoz J, De Guibert S, Vose JM, Bartlett NL, et al. . Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 2021;194:690–700.
- Topp MS, van Meerten T, Houot R, Minnema MC, Bouabdallah K, Lugtenburg PJ, et al. . Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol 2021;195:388–98.
- Neelapu SS, Tummala S, Kebriaei P, Wierda WG, Gutierrez C, Locke FL, et al. . Chimeric antigen receptor T-cell therapy — assessment and management of toxicities. Nat Rev Clin Oncol 2018;15:47–62.
- Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, et al. . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer 2020;8:e001511.
- Ruark J, Mullane E, Cleary N, Cordeiro A, Bezerra ED, Wu V, et al. . Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy. Biol Blood Marrow Transplant 2020;26:34–43.
- Wang XS, Srour SA, Whisenant M, Subbiah IM, Chen TH, Ponce D, et al. . Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies. Transplant Cell Ther 2021;27:930.
- Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, et al. . Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2020;4:629–37.
- Patrick DL, Powers A, Jun MP, Kim Y, Garcia J, Dehner C, et al. . Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. Blood Adv 2021;5:2245–55.
- Dueck AC, Kumar SK, Lin Y, Siddiqui M, Bennani NN, Yost KJ, et al. . Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. stem cell transplant: longitudinal patient reported adverse events, cognition and quality of life. Blood 2019;134:794.
- Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. . Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med 2022;386:629–39.
- Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Crotta A, et al. . Improved quality of life (QOL) with lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, compared with standard of care (SOC) as second-line (2L) treatment in patients (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the phase 3 TRANSFORM study. Blood 2021;138:3845.
- Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, et al. . Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity. J Clin Oncol 2022;40(16_suppl):7571).
- Lunning MA, Wang H-L, Hu Z-H, Locke FL, Siddiqi T, Jacobson CA, et al. . Outcomes of axicabtagene ciloleucel in comparison with chemoimmunotherapy (CIT) in an elderly population for treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of prior therapy. Blood2022;140:1852–5.
- Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–86.
Source: PubMed